Abstract
The prion protein is a cell surface glycoprotein that is converted to a protease resistant abnormal isoform during the course of prion disease. The normal isoform of this protein has been shown to be an antioxidant that aids the survival of neurones. The abnormal isoform is associated with both the transmissible agent of prion diseases and is also toxic. Recent studies have shown that there are multiple end states in terms of aggregation of the protein. Both soluble oligomers and insoluble fibrils can form from the abnormal isoform. Although fibrils are characteristic of the disease, the most infectious prions are associated with oligomers. Neurotoxicity can be associated with fibrils but mostly appears to be due to small aggregates. For many years fibrils were believed to be central to the disease process but currently evidence supports the notion that fibrils represent a ‘bulk’ form of abnormal protein, which is largely inert, but carried along a small active component. This review will examine what is known about the mechanisms behind prion protein aggregation, and the relevance of each form for the disease.
Keywords: Prion, aggregation, fibril, oligomer, structure, neurotoxicity
Protein & Peptide Letters
Title: Mechanisms of Prion Protein Aggregation
Volume: 16 Issue: 1
Author(s): Sarah N. Fontaine and David R. Brown
Affiliation:
Keywords: Prion, aggregation, fibril, oligomer, structure, neurotoxicity
Abstract: The prion protein is a cell surface glycoprotein that is converted to a protease resistant abnormal isoform during the course of prion disease. The normal isoform of this protein has been shown to be an antioxidant that aids the survival of neurones. The abnormal isoform is associated with both the transmissible agent of prion diseases and is also toxic. Recent studies have shown that there are multiple end states in terms of aggregation of the protein. Both soluble oligomers and insoluble fibrils can form from the abnormal isoform. Although fibrils are characteristic of the disease, the most infectious prions are associated with oligomers. Neurotoxicity can be associated with fibrils but mostly appears to be due to small aggregates. For many years fibrils were believed to be central to the disease process but currently evidence supports the notion that fibrils represent a ‘bulk’ form of abnormal protein, which is largely inert, but carried along a small active component. This review will examine what is known about the mechanisms behind prion protein aggregation, and the relevance of each form for the disease.
Export Options
About this article
Cite this article as:
Fontaine N. Sarah and Brown R. David, Mechanisms of Prion Protein Aggregation, Protein & Peptide Letters 2009; 16 (1) . https://dx.doi.org/10.2174/092986609787049411
DOI https://dx.doi.org/10.2174/092986609787049411 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Animal Models for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets The Novel Synthesized Pyridazinone Derivates had the Antiproliferative and Apoptotic Effects in SHSY5Y and HEP3B Cancer Cell Line
Letters in Organic Chemistry Withdrawal Notice: Role, Significance and Association of microRNA-10a/b in Physiology of Cancer
MicroRNA Neuronal Membranes are Key to the Pathogenesis of Alzheimers Disease: the Role of Both Raft and Non-Raft Membrane Domains
Current Alzheimer Research The Role of Clusterin in Carcinogenesis and its Potential Utility as Therapeutic Target
Current Medicinal Chemistry Novel Lactulose and Melibiose Targeting Autophagy to Reduce PolyQ Aggregation in Cell Models of Spinocerebellar Ataxia 3
CNS & Neurological Disorders - Drug Targets Effects of Proteoglycans on Oxidative/Nitrative Stress
Current Organic Chemistry Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics
Current Medicinal Chemistry Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers
Current Pharmaceutical Design Current and Potential Treatments for Cervical Cancer
Current Cancer Drug Targets Targeting p73 - a Potential Approach in Cancer Treatment
Current Pharmaceutical Design The Safety of Medications for the Treatment of Bipolar Disorder During Pregnancy and the Puerperium
Current Drug Safety APP-Based Neuroprotective Strategies
Current Alzheimer Research Influence of Trishomocubanes on Sigma Receptor Binding of N-(1-Benzylpiperidin- 4-yl)-4-[123I]iodobenzamide In Vivo in the Rat Brain
Medicinal Chemistry Transglutaminase-Catalyzed Crosslinking in Neurological Disease: From Experimental Evidence to Therapeutic Inhibition
CNS & Neurological Disorders - Drug Targets Polyphenols Beyond Barriers: A Glimpse into the Brain
Current Neuropharmacology Emerging Therapy for Diabetic Neuropathy: Cell Therapy Targeting Vessels and Nerves
Endocrine, Metabolic & Immune Disorders - Drug Targets Synthesis and Biological Evaluation of Acridine/Acridone Analogs as Potential Anticancer Agents
Medicinal Chemistry Therapeutic Potential of Ferulic Acid in Alzheimer's Disease
Current Drug Delivery Novel Natural and Synthetic Ligands of the Endocannabinoid System
Current Medicinal Chemistry